FTC moves to block Edwards' proposed JenaValve acquisition; Edwards raises FY2025 adjusted EPS guidance to $2.45-$2.55

Edwards Lifesciences Corp

FTC moved to block Edwards' proposed acquisition of JenaValve Technology; Edwards disagrees and will continue pursuing regulatory approval.
Edwards estimates a final determination on the acquisition by end of Q1 2026.
Full-year 2025 adjusted EPS guidance raised to high-end of $2.45-$2.55 (from $2.40-$2.50); revenue guidance unchanged.
Minimal impact to Q3 2025 adjusted EPS guidance from FTC action.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.